SAN DIEGO, CA – April 2, 2014 – GLYSENS INCORPORATED is profiled in a feature article in today”s edition of MedCity News by author Karen Heyman, entitled, “No more needles: Startup tests implant that can measure blood sugar for up to a year.”

Several times every day, many of the nearly 19 million Americans diagnosed with diabetes have to check their glucose levels. Even though this task can be life-saving, patients are often reluctant to do it regularly. Existing methods are either painful (pricking a finger for a blood sample) or cumbersome (implanted sensors that require frequent replacement).  Joseph Y. Lucisano and David A. Gough believe they have a better way.  They are the co-founders of GlySens Incorporated, and hold 18 monitoring and related technology patents.  They have developed an implanted glucose monitoring system that can work for over a year before requiring a change.  If successful, it will join a market projected to reach $568.5 million globally by 2020, according to Allied Market Research.

“What we hope to deliver to people with diabetes is freedom. To give them some time in their day when they can hopefully be free from remembering they have diabetes,” Lucisano said. “The more people that use our product and forget that they’re using it — that’s what we’ll count as success.”  Read more…